Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. (ALLO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
allo · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Allogene Therapeutics, Inc. (ALLO) measures how much investors pay for each dollar of the company's trailing earnings. ALLO's current PE ratio of N/A is calculated by dividing its stock price of $1.85 by its TTM earnings per share of -$0.72.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2017 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Allogene Therapeutics, Inc.You ALLO | $451M | N/A | — | -$0.72 |
 Achieve Life Sciences, Inc. ACHV | $562M | N/A | — | -$1.25 |
 Atea Pharmaceuticals, Inc. AVIR | $353M | N/A | — | -$1.94 |
 Cabaletta Bio, Inc. CABA | $523M | N/A | — | -$1.64 |
 Caribou Biosciences, Inc. CRBU | $184M | N/A | — | -$1.59 |
 Editas Medicine, Inc. EDIT | $262M | N/A | — | -$1.80 |
 Humacyte, Inc. HUMA | $237M | N/A | — | -$0.26 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.87 | — | |
2024-12-31 FY2024 | — | $-1.32 | — | |
2023-12-31 FY2023 | — | $-2.09 | — | |
2022-12-31 FY2022 | — | $-2.38 | — | |
2021-12-31 FY2021 | — | $-1.34 | — | |
2020-12-31 FY2020 | — | $-2.08 | — | |
2019-12-31 FY2019 | — | $-1.83 | — | |
2018-12-31 FY2018 | — | $-2.36 | — | |
2017-12-31 FY2017 | — | $-0.00 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Allogene Therapeutics, Inc. (ALLO) measures how much investors pay for each dollar of the company's trailing earnings. ALLO's current PE ratio of N/A is calculated by dividing its stock price of $1.85 by its TTM earnings per share of -$0.72.
Frequently asked questions
ALLO pe ratio · 6 questionsALLO's current PE ratio is N/A as of 2026-06-08, based on a stock price of $1.85 and TTM EPS of -$0.72. Data sourced from Financial Modeling Prep via ALLO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Allogene Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08